Exagen's Revenue Jumps, But Losses Widen Amid Higher Costs

TL;DR

**Exagen is burning cash despite strong revenue growth, making it a risky bet until they prove a path to profitability.**

AI Summary

EXAGEN INC. reported a significant increase in revenue for the three months ended September 30, 2025, reaching $17.244 million, up from $12.507 million in the prior year, representing a 37.9% increase. For the nine months ended September 30, 2025, revenue grew to $49.944 million from $41.986 million, an 18.9% increase. Despite revenue growth, the company's net loss widened to $7.087 million for the three-month period, compared to $5.028 million in 2024, and to $15.278 million for the nine-month period, up from $11.354 million. This increased loss was driven by higher operating expenses, including selling, general and administrative expenses rising to $11.445 million from $10.163 million, and a substantial increase in interest expense to $1.319 million from $0.562 million. A new warrant liability of $6.634 million also contributed to the increased total liabilities of $44.685 million as of September 30, 2025, up from $35.149 million at December 31, 2024. The company secured $18.6 million in net proceeds from a public offering in May 2025 and an initial $25.0 million term loan from Perceptive Credit Holdings IV, LP in April 2025, improving its cash and cash equivalents to $35.652 million from $22.036 million at year-end 2024. However, the company continues to incur recurring losses and negative cash flows from operating activities, with an accumulated deficit of $309.6 million.

Why It Matters

Exagen's ability to significantly grow revenue, with a 37.9% increase in Q3 2025, demonstrates strong market demand for its AVISE brand diagnostic tests, particularly the AVISE CTD test which accounts for 87% of revenue. However, the widening net losses and increased operating expenses, including a new $6.634 million warrant liability, raise concerns about profitability and operational efficiency. For investors, this mixed performance signals a growth-oriented company still struggling with the path to profitability, potentially impacting stock valuation. Employees might see continued investment in R&D and commercialization, but also pressure to control costs. Customers benefit from continued product availability, but the company's financial health could influence future innovation. Competitors will be watching Exagen's ability to convert revenue growth into sustainable profits in the competitive medical technology space.

Risk Assessment

Risk Level: high — The company has incurred recurring losses and negative cash flows from operating activities since inception, with an accumulated deficit of $309.6 million as of September 30, 2025. Net loss widened to $7.087 million for the three months ended September 30, 2025, from $5.028 million in the prior year, and net cash used in operating activities was $10.612 million for the nine months ended September 30, 2025. The company also recognized a significant change in fair value of warrant liability of $2.670 million for the quarter.

Analyst Insight

Investors should exercise caution and closely monitor Exagen's next few quarters for signs of improved cost management and a clear path to profitability. While revenue growth is positive, the increasing net losses and significant accumulated deficit suggest that the company is still in a high-risk, growth-at-all-costs phase. Consider waiting for evidence of reduced cash burn and a narrowing net loss before making a significant investment.

Financial Highlights

debt To Equity

2.46

revenue

$17.244M

operating Margin

-18.0%

total Assets

$62.823M

total Debt

$29.095M

net Income

$-7.087M

eps

$-0.31

gross Margin

58.4%

cash Position

$35.652M

revenue Growth

+37.9%

Revenue Breakdown

Key Numbers

• $17.244M — Revenue (Q3 2025) (Increased 37.9% from $12.507M in Q3 2024)
• $7.087M — Net Loss (Q3 2025) (Widened from $5.028M in Q3 2024)
• $309.6M — Accumulated Deficit (As of September 30, 2025, indicating historical losses)
• $35.652M — Cash and Cash Equivalents (Increased from $22.036M at December 31, 2024, due to financing activities)
• $6.634M — Warrant Liability (New liability as of September 30, 2025, impacting total liabilities)
• 37.9% — Revenue Growth (Q3 YoY) (Percentage increase in revenue for the three months ended September 30, 2025)
• $1.319M — Interest Expense (Q3 2025) (Increased from $0.562M in Q3 2024, contributing to wider losses)
• $18.6M — Net Proceeds from Public Offering (Received in May 2025, bolstering cash reserves)
• $25.0M — Initial Term Loan (Funded by Perceptive Credit Holdings IV, LP in April 2025)
• 87% — AVISE CTD Revenue Contribution (Q3 2025) (Percentage of total revenue from the AVISE CTD test)

Key Players & Entities

• EXAGEN INC. (company) — registrant
• Perceptive Credit Holdings IV, LP (company) — debt provider
• SEC (regulator) — Securities and Exchange Commission
• $17.244 million (dollar_amount) — revenue for three months ended September 30, 2025
• $12.507 million (dollar_amount) — revenue for three months ended September 30, 2024
• $7.087 million (dollar_amount) — net loss for three months ended September 30, 2025
• $5.028 million (dollar_amount) — net loss for three months ended September 30, 2024
• $309.6 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $35.652 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• AVISE CTD (company) — primary diagnostic test product

FAQ

Risk Factors

• Increasing Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $7.087 million for Q3 2025, an increase from $5.028 million in Q3 2024. The accumulated deficit stands at $309.6 million as of September 30, 2025, indicating a history of unprofitability and raising concerns about long-term financial sustainability.
• Rising Operating Expenses [medium — financial]: Selling, general, and administrative expenses increased to $11.445 million in Q3 2025 from $10.163 million in Q3 2024. Research and development expenses also grew to $1.730 million from $1.481 million, contributing to the widening net loss despite revenue growth.
• Increased Interest Expense and Debt [medium — financial]: Interest expense more than doubled to $1.319 million in Q3 2025 from $0.562 million in Q3 2024. Total liabilities increased to $44.685 million from $35.149 million, partly due to a new $6.634 million warrant liability, indicating a growing debt burden.
• Dependence on Financing Activities [high — financial]: While cash and cash equivalents increased to $35.652 million due to a $18.6 million public offering and a $25.0 million term loan, the company continues to incur recurring losses and negative cash flows from operations, suggesting ongoing reliance on external funding.
• Healthcare Regulatory Environment [medium — regulatory]: As a diagnostics company, Exagen is subject to stringent regulations from bodies like the FDA and CMS. Changes in reimbursement policies, regulatory approvals, or compliance requirements could significantly impact revenue and operations.
• Competition in Diagnostic Testing [medium — market]: The diagnostic testing market is competitive, with established players and emerging technologies. Exagen's ability to maintain market share and grow revenue depends on the efficacy, cost-effectiveness, and adoption of its AVISE CTD test.

Industry Context

Exagen operates in the molecular diagnostics sector, focusing on autoimmune and autoimmune-related diseases. The market is characterized by rapid technological advancements, increasing demand for personalized medicine, and evolving reimbursement landscapes. Key competitors include larger diagnostic companies and specialized labs, all vying for market share through innovation and strategic partnerships.

Regulatory Implications

As a healthcare diagnostics provider, Exagen faces significant regulatory scrutiny. Compliance with FDA regulations for diagnostic tests, CLIA certifications, and evolving reimbursement policies from CMS and private payers are critical. Any adverse changes in these areas could materially impact revenue and operational costs.

What Investors Should Do

1. Monitor expense management closely.
2. Evaluate the sustainability of cash burn.
3. Assess the impact of warrant liability.
4. Track AVISE CTD adoption and market penetration.

Key Dates

• 2025-04-01: Secured $25.0 million term loan — Provided significant capital infusion to support operations and growth initiatives.
• 2025-05-01: Completed public offering — Raised $18.6 million in net proceeds, further strengthening the company's cash position.
• 2025-09-30: Quarterly financial reporting — Showcased substantial revenue growth but also a widening net loss and increased liabilities, including a new warrant liability.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates Exagen's historical unprofitability, standing at $309.6 million as of September 30, 2025.)

Warrant liability

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. It is recorded as a liability when issued. (A new liability of $6.634 million was recognized as of September 30, 2025, contributing to increased total liabilities.)

AVISE CTD

Exagen's proprietary diagnostic test for connective tissue diseases. (This test is the primary revenue driver, accounting for 87% of total revenue in Q3 2025.)

Operating lease right-of-use assets

An asset recognized under accounting standards for the right to use an asset for the lease term, typically for property or equipment. (Represents the value of leased assets, with a balance of $1.685 million as of September 30, 2025.)

Change in fair value of warrant liability

The unrealized gain or loss resulting from changes in the estimated market value of outstanding warrants. (A charge of $2.670 million was recorded for Q3 2025, impacting net loss.)

Year-Over-Year Comparison

Compared to the prior year, Exagen Inc. has demonstrated robust revenue growth, with Q3 2025 revenue up 37.9% year-over-year to $17.244 million. However, this top-line growth has been overshadowed by a widening net loss, which increased from $5.028 million in Q3 2024 to $7.087 million in Q3 2025. This is primarily due to significant increases in operating expenses, particularly SG&A, and a substantial rise in interest expense. New risks have emerged, including a $6.634 million warrant liability, contributing to higher total liabilities.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share XGN The Nasdaq Global Market

Filing Documents

• exdx-20250930.htm (10-Q) — 996KB
• xgn311-093025.htm (EX-31.1) — 12KB
• xgn312-093025.htm (EX-31.2) — 12KB
• xgn321-093025.htm (EX-32.1) — 10KB
• 0001274737-25-000071.txt ( ) — 6548KB
• exdx-20250930.xsd (EX-101.SCH) — 41KB
• exdx-20250930_cal.xml (EX-101.CAL) — 61KB
• exdx-20250930_def.xml (EX-101.DEF) — 244KB
• exdx-20250930_lab.xml (EX-101.LAB) — 651KB
• exdx-20250930_pre.xml (EX-101.PRE) — 462KB
• exdx-20250930_htm.xml (XML) — 847KB

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements 1 Unaudited Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 1 Unaudited Condensed Statements of Operations for the Three and Nine Months ended September 30, 2025 and 2024 2 Unaudited Condensed Statements of Stockholders' Equity for the Three and Nine Months ended September 30, 2025 and 2024 3 Unaudited Condensed Statements of Cash Flows for the Nine Months ended September 30, 2025 and 2024 5 Notes to Unaudited Condensed Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 34

Controls and Procedures

Item 4. Controls and Procedures 35

Other Information

Part II. Other Information

Legal Proceedings

Item 1. Legal Proceedings 36

Risk Factors

Item 1A. Risk Factors 36

Other Information

Item 5. Other Information 37

Exhibits

Item 6. Exhibits 38

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements Exagen Inc. Unaudited Condensed Balance Sheets (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 35,652 $ 22,036 Accounts receivable, net 11,092 7,835 Prepaid expenses and other current assets 5,845 6,584 Total current assets 52,589 36,455 Property and equipment, net 7,494 5,283 Operating lease right-of-use assets 1,685 2,401 Other assets 1,055 550 Total assets $ 62,823 $ 44,689 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,559 $ 4,137 Accrued and other current liabilities 5,684 6,916 Deferred revenue 641 733 Finance lease liabilities, current 1,134 201 Operating lease liabilities, current 1,192 1,096 Borrowings, current 680 423 Total current liabilities 12,890 13,506 Borrowings, non-current, net of discounts and debt issuance costs 22,261 19,822 Finance lease liabilities, non-current 2,141 157 Operating lease liabilities, non-current 759 1,664 Warrant liability 6,634 — Total liabilities 44,685 35,149 Commitments and contingencies (Note 5) Stockholders' equity: Preferred stock, $ 0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value per share; 200,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 22,510,313 and 17,640,328 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 23 18 Additional paid-in capital 327,724 303,853 Accumulated deficit ( 309,609 ) ( 294,331 ) Total stockholders' equity 18,138 9,540 Total liabilities and stockholders' equity $ 62,823 $ 44,689 The accompanying notes are an integral part of these unaudited condensed financial statements 1 Exagen Inc. Unaudited Condensed Statements of Operations (in thousands, except share and per share amounts) Three Months Ended Septem

View Full Filing

View this 10-Q filing on SEC EDGAR